[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@Gantosj "$CRDL in a consolidation mode above its 200MA after the XXX% move from the 52W low We are waiting for the #Myocarditis data in this Q. Meanwhile the Ph-3 trial in acute #Pericarditis continue to recruit patients"
@Gantosj on X 2025-07-03 14:22:05 UTC 13.3K followers, 3238 engagements

"$CNVIF $CNVI.v Capital structure Way undervalued when we look at many M&A deals in cardiovacular space & many large medical devices would try to get the hybrid device & add it to their imaging portfolio that gives CNVI a multibagger potential in a very short time"
@Gantosj on X 2025-06-12 18:19:34 UTC 13.3K followers, 4560 engagements

"$SRPT Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term Sustainable Growth and Provides Update on ELEVIDYS Label"
@Gantosj on X 2025-07-16 20:03:12 UTC 13.3K followers, 4208 engagements

"This is the next step I was looking for from $EPRX moving to Ph-2b placebo-controlled study Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis #EoE"
@Gantosj on X 2025-07-08 12:13:48 UTC 13.3K followers, 2796 engagements

"Here we go $LIB $VLTLF LibertyStream Announces Successful Field Trial in North Dakota's Bakken Region"
@Gantosj on X 2025-07-17 17:23:17 UTC 13.3K followers, 4015 engagements

"And $VLTLF $LIB is breaking out the 200MA on a huge volume both in the US & Canada Is it the inflection point $VLT:F's investors were waiting for Let's see what they have in the next few weeks"
@Gantosj on X 2025-07-18 19:59:43 UTC 13.3K followers, 2809 engagements

"$VLTLF $LIB The street starts digesting yesterday's news & realize the low valuation of this company despite the outstanding progress in the past XX months reaching the inflection point with its 10K barrels/day unit"
@Gantosj on X 2025-07-18 14:48:38 UTC 13.3K followers, 4653 engagements

"$EPRX is one of the best runners in 2025 so far with over XXX% from the 52W-low U$2.20 to 52W-H $XXXX Now it's flagging preparing for the next move. Waiting for the next data release it's very important point to see how impressive was cohort-8 dose to choose it for the next Ph-2b trial"
@Gantosj on X 2025-07-14 14:26:33 UTC 13.3K followers, 5203 engagements

"Indeed $LVLTF's CEO kept mentioning "production by YE2024" that will bring in cashflow as they scaling-up the DLE unit"
@Gantosj on X 2024-08-29 18:48:09 UTC 13.3K followers, 3085 engagements

"This XXXX% tariff is BULLISH for $VLTLF $LIB As a domestic US producer of #Lithium in Texas & North-Dakota this tariff is not an issue & double the lithium prices in the US"
@Gantosj on X 2025-07-17 18:32:21 UTC 13.3K followers, 1977 engagements

"$LVLTF $LIB This is a very important confirmation that the DLE unit is working "More than 1300 DLE cycles have now been completed across six months of U.S. field operations underscoring scalability." The average lithium content of the processed brine at the site in North-Dakota was 75mg/L vs $30mg/L in Texas"
@Gantosj on X 2025-07-17 18:05:55 UTC 13.3K followers, 4022 engagements

"Yes $IBAT to suspend operations at lithium extraction plant on weak prices since their cost is very high While $VLTLF $VLT.v has a very low cost of $2900/tonne All-in extraction and operating costs below US$2900 per tonne LCE supporting robust margins even within a volatile #lithium price environment"
@Gantosj on X 2024-09-26 13:57:34 UTC 13.3K followers, 2010 engagements

"$CRDLs current valuation barely reflects the significant progress in its #pericarditis program which has already advanced to Ph-3. If the upcoming Ph-2 #myocarditis data turns out positive the stock could see a rapid re-rating to the upside. The Ph-3 trial for recurrent pericarditis is considered highly de-risked thanks to the robust results from the earlier open-label Ph-2 study which closely mirrors the approach used by an already approved IL-1 blocker"
@Gantosj on X 2025-07-22 13:53:13 UTC 13.3K followers, 3908 engagements

"And the first breakout is here $CRDL breaking out the $XXXX resistance line & heading north to test the 200MA around $1.45"
@Gantosj on X 2025-06-04 17:23:36 UTC 13.3K followers, 2570 engagements

"$SRPT Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants X Years Old at Time of Treatment"
@Gantosj on X 2025-05-16 13:02:45 UTC 13.3K followers, 7848 engagements

"The day the street understands that $VLTLF $LIB's DLE is the cheapest way in the world to extract #Lithium which is a critical mineral for the US where China controls XX% of the world production then US Government will push $VLTLF & support their DEL"
@Gantosj on X 2025-07-18 15:19:49 UTC 13.3K followers, 4398 engagements

"$CNVIF $CNVI Conavi Medical Applauds New American Journal of Cardiology Study Highlighting Importance of Intracoronary Imaging During PCI"
@Gantosj on X 2025-07-23 11:20:07 UTC 13.3K followers, 2831 engagements

"$CRDL Topline results are expected within the next two weeks. Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute #Myocarditis"
@Gantosj on X 2025-07-22 11:33:32 UTC 13.3K followers, 2662 engagements

"$CNVI.v $CNVIF's CEO: "The market risk is really low at this level. In fact it's a hot time in the market for products like ours. Our technology risk has been retired with regard to our next generation development & regulatory risk will be low because we have a 510K application with our own product at as its predicate and lastly our our finance or capital risk has been reduced because we have just raised $XX million in financing.""
@Gantosj on X 2025-07-03 18:22:02 UTC 13.3K followers, 2234 engagements

"Strong performance for $VLTLF $LIB today up XXXXX% on robust volume. 397K in the US and over 656K in Canada It certainly appears that sophisticated investors are stepping in and loading up signaling renewed confidence and momentum in the stock. #StockMarket #Investing #Lithium #Minerals #RareEarths"
@Gantosj on X 2025-07-18 18:46:20 UTC 13.3K followers, 6906 engagements

"The momentum at $EPRX since I met the management team at #BloomBurton conference in early May is so impressive Now the Ph-2b placebo-controlled study is underway but more data will come soon A steady flow of data from the Ph-2a open-label trial (Cohorts 59) will continue to roll out. This includes: * Histology scores (EoEHSS and PEC) at X X and XX months * Symptom scores (SDI) at X X X and XX months These data sets will be grouped and released roughly every 3-months over the coming year. The next data release is anticipated in September 2025"
@Gantosj on X 2025-07-08 15:38:48 UTC 13.3K followers, 3837 engagements

"$CRI.v $CRICF is up XX% today to C$0.07 on a huge volume 4M shares Tells the real story behind their interesting discovery of one of the largest #antimony deposits that is classified as #CriticalMinerals sophisticated Investors are piling up their position & move the price higher than last week private-placement at $XXXX (no warrants)"
@Gantosj on X 2025-07-02 16:37:05 UTC 13.3K followers, 6526 engagements

"HCW analyst Brandon Folkes-CFA choose $EPRX as his top pick for 2H25 & TP US$12 "Eupraxia has the potential for a best-in-class treatment for the ever-growing eosinophilic esophagitis ( #EoE) market and has shown the potential for an annual treatment of EP-104GI.""
@Gantosj on X 2025-07-14 16:23:04 UTC 13.3K followers, 2159 engagements

"Nice $ASTS at $XXXX is a great point to be my friend Keep holding tight we can sell those shares for several 100s dollars in 2027-2028 😇"
@Gantosj on X 2025-07-17 15:46:35 UTC 13.3K followers, 2032 engagements

"A sleek & professional website moving from $VLTLF $VLT.v to $LIB Liberty Stream Infrastructure Partners Take a look at the expanded list of minerals beside #Lithium. A huge opportunity in the making"
@Gantosj on X 2025-06-30 13:14:21 UTC 13.3K followers, 2329 engagements

"Great move by $CRDL up XX% after the news this morning locking database from its Ph-2 pericarditis trail & topline results within X weeks"
@Gantosj on X 2025-07-22 16:11:42 UTC 13.3K followers, 2002 engagements

"$SRPT Sarepta Therapeutics to Announce First Quarter 2025 Financial Results Tuesday May X 2025. and conference call at 4:30pm ET"
@Gantosj on X 2025-04-22 12:57:43 UTC 13.3K followers, 1938 engagements

"$CRDL bouncing up from its 50MA after X weeks of consolidation with high volume of 150K shares in the 1st XX minutes Waiting for the myocarditis data"
@Gantosj on X 2025-05-28 13:44:52 UTC 13.3K followers, 1727 engagements

"The $1.25B $PFE deal with Chinas 3SBio highlights big pharmas aggressive pursuit of bi-specific drugs to gain a competitive edge in cancer therapy This underscores the huge potential of $MDNA.to $MDNAF's MDNA113 a first-in-class tumor-targeting conditionally activated anti-PD1-IL-2 Superkine. Designed to enhance the therapeutic index MDNA113 combines PD-1 blockade with a tumor-specific IL-2 Superkine to boost T-cell/NK cell activity in cold tumors like glioblastoma and pancreatic cancer with preclinical data showing potent immune activation. As bispecifics drive biotech momentum $MDNAF's"
@Gantosj on X 2025-05-20 15:39:23 UTC 13.3K followers, 5765 engagements

"So what we should look at from $CRDL's acute #myocarditis Ph-2 data The X primary outcome measures of the trial which were evaluated following XX weeks of double-blind therapy consist of cardiac MRI parameters: global longitudinal strain and extra-cellular volume which assess myocardial function and tissue characteristics associated with fibrosis and inflammation. Both parameters are recognized prognostic markers in patients with acute myocarditis"
@Gantosj on X 2025-07-22 12:58:26 UTC 13.3K followers, 8305 engagements

"$CRDL There are no FDA-approved drug therapies indicated for the treatment of acute myocarditis. Acute #myocarditis is a potentially life-threatening condition affecting the heart muscle (myocardium) and is characterized by chest pain shortness of breath fatigue rapid or irregular heartbeat (arrhythmias) and light-headedness and can lead to heart failure or sudden cardiac death"
@Gantosj on X 2025-07-22 11:38:59 UTC 13.3K followers, 3512 engagements

"$SRPT is eligible to receive up to $103.5M in near-term regulatory and commercial milestone payments Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS a Gene Therapy to Treat Duchenne Muscular Dystrophy"
@Gantosj on X 2025-05-13 13:47:36 UTC 13.3K followers, 2762 engagements

"$CRDL is getting close to release the Myocarditis data and continue with the positive momentum after the bounce off the 50MA Next target is the 200MA around $XXXX after breaking out the $XXXX resistanc eline"
@Gantosj on X 2025-06-03 16:28:58 UTC 13.3K followers, 7403 engagements

"Things are starting to get real. The FDA has now acknowledged a connection between COVID-19 vaccines and the increase in pericarditis and myocarditis cases among young people. On the bright side it's great to see $CRDL making solid progress with their #Pericarditis study already deep into Ph-3. Next important step Release the #Myocarditis data and see if they can build on their pericarditis success Potentially unlocking another major therapeutic win 🤞"
@Gantosj on X 2025-07-21 19:00:13 UTC 13.3K followers, 2652 engagements

"I look at it in a different way Dr. Garnett wouldnt be joining $CRDL's Board unless he saw major potential ahead and its clear hes excited about the prospects of Acute Pericarditis as it advances into the Phase X trial"
@Gantosj on X 2025-05-29 14:25:27 UTC 13.3K followers, 2314 engagements

"$NVS FDA approved Zolgensma for SMA $AVXS Next we will see the pricing $SRPT"
@Gantosj on X 2019-05-24 16:34:51 UTC 13.3K followers, XX engagements